Show simple item record

dc.contributor.authorJoshi, Shilpa
dc.contributor.authorUpadhyaya, K. S. Vasudeva
dc.contributor.authorManjuladevi, M.
dc.date.accessioned2016-12-05T18:52:40Z
dc.date.available2016-12-05T18:52:40Z
dc.date.issued2015
dc.identifier.citationJoshi, S., Vasudeva Upadhyaya, K., & Manjuladevi, M. (2015). Comparison of neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patients. Indian J Anaesth, 59(3), 165. doi:10.4103/0019-5049.153038en_US
dc.identifier.urihttp://hdl.handle.net/1808/22142
dc.description.abstractBackground and Aims: Obese patients are more vulnerable to residual neuromuscular block (NMB) and its associated complications in the post-operative period. This study was carried out to compare neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patients, objectively using neuromuscular (NM) monitoring. Methods: Twenty female patients each belonging to normal weight, overweight and obese, based on body mass index, requiring general anaesthesia were recruited for this prospective cross sectional study. NMB was induced with vecuronium (0.1 mg/kg) dose based on patient's real body weight (RBW) and monitored using acceleromyographic train of four (TOF). All patients received neostigmine 40 μg/kg and glycopyrrolate 10 μg/kg at 25% of spontaneous recovery of first twitch height (T1) of TOF (DUR 25%) and were allowed to recover to TOF ratio of 0.9. Statistical analysis was done using analysis of variance test. Results: Recovery of TOF ratio to 0.5 was comparable in all three groups. Recovery of TOF ratio to 0.7 was delayed in obese (9.82 ± 3.21 min) compared with normal weight group (7.50 ± 2.52 min). Recovery of TOF to 0.9 was significantly delayed in both overweight (12.18 ± 4.29 min) and obese patients (13.78 ± 4.30 min). DUR 25% was significantly longer in overweight (mean, standard deviation [range]; 30.10 [19-40 min]) and obese (28.8 [12-45 min]) compared with normal weight patients (22.75 [16-30 min]). Conclusion: In overweight and obese patients, when vecuronium induction dose is based on RBW, neostigmine induced recovery of NMB is delayed in late phases (TOF 0.7-0.9), which may result in vulnerability for associated complications of incomplete recovery. Ensuring safe recovery thus requires objective NM monitoring.en_US
dc.publisherMedknow Publicationsen_US
dc.rights© Creative Commons Attribution Non-Commercial Share Alike Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectNeostigmineen_US
dc.subjectneuromuscular monitoringen_US
dc.subjectobesityen_US
dc.subjectvecuronium bromideen_US
dc.titleComparison of neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patientsen_US
dc.typeArticleen_US
kusw.kuauthorJoshi, Shilpa
kusw.kudepartmentPharmaceutical Chemistryen_US
dc.identifier.doi10.4103/0019-5049.153038en_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© Creative Commons Attribution Non-Commercial Share Alike License
Except where otherwise noted, this item's license is described as: © Creative Commons Attribution Non-Commercial Share Alike License